Lymphoma Archives | Report Store | Pharma intelligence

Market Spotlight: Hodgkin’s Lymphoma

This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, and probability of success, as well as presenting drug-specific revenue forecasts.

January 15, 2021

Find out more

Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)

$1,318.00

This Market Spotlight report covers the Peripheral T-Cell Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

January 15, 2021

Find out more

Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)

$1,318.00

This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

January 7, 2021

Find out more

Market Spotlight: Mantle Cell Lymphoma

$1,318.00

This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

January 7, 2021

Find out more

Market Spotlight: Waldenström Macroglobulinemia (WM)

$1,318.00

This Market Spotlight report covers the Waldenström Macroglobulinemia (WM) market, comprising key marketed and pipeline drugs, probability of success, clinical trials, upcoming events, recent events and analyst opinion, a 10-year disease incidence forecast, and presenting drug-specific revenue forecasts.

January 7, 2021

Find out more

NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026

Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL). It is the second most common type of NHL after diffuse large B-cell lymphoma (DLBCL), and accounts for more than 20% of all NHL cases.

January 30, 2019

Find out more

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034

Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes.

October 9, 2018

Find out more

NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034

Mantle cell lymphoma (MCL) is a rare form of B-cell non-Hodgkin’s lymphoma (NHL), accounting for 3–6% of new NHL cases.

April 11, 2018

Find out more

Hodgkin’s Lymphoma Disease Coverage Forecast and Market Analysis to 2034

Hodgkin’s lymphoma (HL) is a lymphoid malignancy. HL most commonly affects contiguous lymph node groups, but may also affect tissues.

October 3, 2016

Find out more